Latest News

• Early Development Led by the PCCTC, FDA Approval Now Sought for A...

  Press Releases by Jason Harris - OncLive October 12, 2017

  

  A new drug application (NDA) has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (C...

  Learn More

• 7th Annual Prostate Cancer Advocacy Symposium: A National Summit ...

  Press Releases by admin September 12, 2017

  

  The 7th Annual Prostate Cancer Advocacy Symposium: A National Summit in Detroit brings together patients and spouses; local, national, and international advocat...

  Learn More

• The PCCTC Selects Tempus as Sequencing and Analytics Provider for...

  Press Releases by Tempus August 17, 2017

  

  Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announc...

  Learn More

• Dr. Howard I. Scher on the Definition of Castration-Sensitive/Nai...

  Press Releases by UroToday August 7, 2017

  

  The PCCTC's Scientific Oversight Committee chair speaks with UroToday at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerla...

  Learn More

• PCCTC Trial Establishes Safety, Antitumor Activity of Apalutamide...

  Press Releases by admin July 25, 2017

  

  Study represents a new standard that demonstrates the patient experience, useful for physicians when considering options to continue treatment until the patient...

  Learn More

• Dr. Lorelei Mucci Discusses Innovative IRONMAN Registry

  Press Releases by admin July 6, 2017

  

  IRONMAN: An International Registry To Improve Outcomes in Men with Advanced Prostate Cancer...

  Learn More